Q3 2026 highlights

GSK delivers strong Q3 performance and continued momentum

Total sales

£8.9bn +5%

Specialty Medicines

£3.9bn +15%

Respiratory, Immunology and Inflammation +21%
Oncology +23%
HIV +10%

Vaccines

£2.6bn -2%

General Medicines

£2.4bn (stable)

Core operating profit

£3.1bn +5%

Total EPS

38.5p -21%

Core EPS

54.6p +1%

Dividend

17p

***Hibsago* approved in US and Japan**, with data showing unprecedented functional cure rates and potential to redefine treatment of chronic hepatitis B

***Jemperli* approved in US** as first immunotherapy for adults with dMMR/MSI-H locally advanced rectal cancer

***Jideytro* approved in US** as second-line treatment for ROS1-positive small-cell lung cancer, with positive data in first-line treatment

Promising first global data for *Riz-Rez* in lung cancer; and **positive phase I data for *Mo-Rez*** in ovarian cancer

On track to start 22 phase III trials in 2026 with 18 starts

Journalists/media see press release on www.gsk.com for full details on Q3 2026.

Please read the cautionary statement regarding forward-looking statements on pages 45 and 46 and the definitions for non-IFRS measures on pages 43 and 44 of the press release

Product group sales may not add to total sales due to rounding.

References to growth are at constant exchange rates (CER) unless stated otherwise.



Luke Miels,
Chief Executive Officer, GSK

"GSK has delivered another strong quarter, with our key growth drivers and new launches performing well. We remain focused on operational delivery, execution and accelerating R&D. Over recent months we have received 3 new specialty medicine approvals in the US: *Hibsago*, which has the potential to transform the treatment of chronic hepatitis B; *Jideytro* in non-small cell lung cancer; and *Jemperli* in rectal cancer. More broadly, in the late-stage portfolio, we are on track to start 22 phase III trials this year."